Skip to Content

Immutep Ltd.

Securities Class Action

  • Date:
  • 7/6/2026
  • Company Name:
  • Immutep Ltd.
  • Stock Symbol:
  • IMMP
  • Class Period:
  • FROM 3/24/2025 TO 3/12/2026
  • Status:
  • Filed
  • Filing Date:
  • 5/5/2026

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Immutep Ltd. (“Immutep” or the “Company”) (NASDAQ:IMMP) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Immutep American Depositary Receipts (“ADRs”) between March 24, 2025 and March 12, 2026, both dates inclusive (the “Class Period”). Investors have until July 6, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
 
According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or concealed the status and prospects of the TACTI004 trial based on continuing positive efficacy and safety readouts of eftilagimod alfa's ("efti") performance in other trials, particularly following positive top-line results from Immutep's prior TACTI-002 and INSIGHT-003 studies. Further, defendants announced in a Form-K filed with the Securities and Exchange Commission in January 30, 2026, that the trial was exhibiting "strong operational progress" and the planned interim futility analysis remained "on track for the first quarter of 2026." In truth, Immutep were aware of or were reckless, based on their access to internal clinical data, analyses, and reports concerning the TACTI-004 trial and its planned interim futility evaluation, that then-existing information materially increased the risk that the study would fail to meet its primary efficacy and/or safety endpoints. When the true details entered the market, the lawsuit claims that investors suffered damages.
 
If you purchased or otherwise acquired Immutep shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out the form below.  There is no cost or obligation to you.
Contact Instructions
Please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com with any questions.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Immutep Ltd. . BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: